[HTML][HTML] The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic …
D Campa, M Gentiluomo, A Stein, MN Aoki… - Critical reviews in …, 2023 - Elsevier
Pancreatic cancer has an incidence that almost matches its mortality. Only a small number of
risk factors and 33 susceptibility loci have been identified. so Moreover, the relative rarity of …
risk factors and 33 susceptibility loci have been identified. so Moreover, the relative rarity of …
Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer
BM Wolpin, C Rizzato, P Kraft, C Kooperberg… - Nature …, 2014 - nature.com
We performed a multistage genome-wide association study including 7,683 individuals with
pancreatic cancer and 14,397 controls of European descent. Four new loci reached genome …
pancreatic cancer and 14,397 controls of European descent. Four new loci reached genome …
Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final …
G Fiorentini, C Aliberti, M Tilli, L Mulazzani… - Anticancer …, 2012 - ar.iiarjournals.org
Background: Metastases to the liver receive most of their blood supply from the arterial route,
therefore for patients with hepatic metastases from large bowel cancer, hepatic arterial …
therefore for patients with hepatic metastases from large bowel cancer, hepatic arterial …
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the …
C Cremolini, C Antoniotti, D Rossini, S Lonardi… - The Lancet …, 2020 - thelancet.com
Background The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus
bevacizumab showed improved outcomes for patients with metastatic colorectal cancer …
bevacizumab showed improved outcomes for patients with metastatic colorectal cancer …
Common variation at 2p13. 3, 3q29, 7p13 and 17q25. 1 associated with susceptibility to pancreatic cancer
EJ Childs, E Mocci, D Campa, PM Bracci, S Gallinger… - Nature …, 2015 - nature.com
Pancreatic cancer is the fourth leading cause of cancer death in the developed world. Both
inherited high-penetrance mutations in BRCA2 (ref.), ATM, PALB2 (ref.), BRCA1 (ref.) …
inherited high-penetrance mutations in BRCA2 (ref.), ATM, PALB2 (ref.), BRCA1 (ref.) …
[HTML][HTML] Multidisciplinary approach of colorectal cancer liver metastases
G Fiorentini, D Sarti, C Aliberti… - World journal of …, 2017 - ncbi.nlm.nih.gov
Large bowel cancer is a worldwide public health challenge. More than one third of patients
present an advanced stage of disease at diagnosis and the liver is the most common site of …
present an advanced stage of disease at diagnosis and the liver is the most common site of …
[HTML][HTML] Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer
Abstract In 2020, 146,063 deaths due to pancreatic cancer are estimated to occur in Europe
and the United States combined. To identify common susceptibility alleles, we performed the …
and the United States combined. To identify common susceptibility alleles, we performed the …
Pet therapy effects on oncological day hospital patients undergoing chemotherapy treatment
M Orlandi, K Trangeled, A Mambrini… - Anticancer …, 2007 - ar.iiarjournals.org
Background: Pet therapy is utilised to improve the quality of life of patients with chronic
diseases. The impact of AAA (animal-assisted activities), a kind of pet therapy, on …
diseases. The impact of AAA (animal-assisted activities), a kind of pet therapy, on …
[HTML][HTML] Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32. 1, 5p15. 33 and 8q24. 21
Genome-wide association studies (GWAS) have identified common pancreatic cancer
susceptibility variants at 13 chromosomal loci in individuals of European descent. To identify …
susceptibility variants at 13 chromosomal loci in individuals of European descent. To identify …
[HTML][HTML] Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial
M Reni, S Cereda, M Milella, A Novarino… - European Journal of …, 2013 - Elsevier
Background New strategies to prolong disease control warrant investigation in patients with
metastatic pancreatic adenocarcinoma. This open-label, randomised, multi-centre phase II …
metastatic pancreatic adenocarcinoma. This open-label, randomised, multi-centre phase II …